vaccin
seriou
viral
infect
measl
mump
hepat
hepat
b
significantli
reduc
incid
diseas
howev
virus
high
rate
mutat
make
vaccin
difficult
task
sinc
viral
infect
overal
impact
easili
develop
resist
current
drug
new
virus
still
appear
perman
need
discoveri
new
drug
also
improv
formul
current
drug
sever
factor
hinder
rapid
develop
antivir
drug
virus
strictli
intracellular
parasit
compos
either
dna
rna
protein
coat
capsid
virus
also
outer
lipid
bilay
membran
extern
coat
call
envelop
nucleic
acid
code
enzym
involv
replic
sever
structur
protein
replic
depend
hostcel
biosynthet
machineri
thu
one
challeng
develop
antivir
agent
identif
step
viral
replic
uniqu
viru
use
normal
cell
among
uniqu
viral
event
attach
penetr
uncoat
rnadirect
dna
synthesi
revers
transcript
rnadirect
rna
synthesi
rna
virus
assembl
releas
intact
virion
exampl
assembl
viru
particl
requir
uniqu
viral
enzym
proteas
led
develop
proteas
inhibitor
moreov
viru
specif
function
make
develop
broadspectrum
antivir
drug
difficult
case
antivir
agent
select
inhibit
uniqu
replic
event
inhibit
dna
polymeras
inhibitor
enzym
take
advantag
fact
viru
synthes
nucleic
acid
rapidli
cell
therefor
rel
greater
inhibit
viral
cellular
dna
antivir
agent
develop
virus
caus
perman
infect
hsv
hiv
exert
antivir
effect
acut
diseas
effect
virus
latenc
result
chronic
infect
period
viru
reactiv
recurr
diseas
requir
longtim
treatment
limit
solubl
antivir
drug
aqueou
media
short
halflif
time
hinder
usag
challeng
develop
new
drug
formul
mani
attempt
improv
physicochem
properti
exist
antivir
drug
order
modifi
bioavail
pharmacokinet
anoth
approach
improv
formul
deliveri
antivir
drug
human
organ
use
controlledreleas
deliveri
system
exampl
nanoparticul
carrier
uniqu
properti
nanomateri
deriv
high
surfacetovolum
ratio
small
size
modifi
surfac
anoth
import
characterist
nanoparticul
carrier
multipl
antivir
agent
incorpor
onto
nanoparticl
also
due
nanometr
size
control
hydrophobicitylipophil
nanoparticl
use
provid
target
specif
biolog
site
thu
systemat
deliveri
special
formul
antivir
therapeut
result
reduct
side
effect
normal
uninfect
cell
nanoparticl
administr
intraven
rout
circul
bloodstream
without
retain
lung
capillari
engulf
mononuclearphagocyt
cell
nanoparticul
deliveri
system
use
carrier
transport
frequent
use
antivir
therapeut
discuss
review
applic
nanomateri
antivir
agent
gener
overview
viral
replic
mechan
action
antivir
agent
present
final
nanoparticul
carrier
use
antivir
therapi
virus
induc
chronic
infect
sever
clinic
manifest
complicationshuman
immunodefici
viru
hiv
hepat
c
viru
hcv
herp
simplex
viru
type
summar
life
cycl
virus
divid
follow
step
adsorpt
attach
penetr
entri
uncoat
product
virion
componentsrepl
transcript
translat
assembl
nake
capsid
virus
nucleocapsid
releas
viral
particl
step
viru
replic
cycl
shown
fig
attach
viral
particl
surfac
host
cell
first
step
everi
viral
infect
interact
requir
adequ
contact
viru
cell
howev
small
percentag
direct
contact
viru
host
cell
lead
success
infect
adsorpt
highli
specif
reaction
involv
attach
surfac
viral
protein
spike
correspond
receptor
surfac
host
cell
receptor
human
virus
mostli
glycoprotein
present
plasma
membran
role
cell
signal
mani
reaction
immun
system
thu
attempt
design
antivir
agent
block
bind
receptor
long
time
must
consid
possibl
loss
normal
cellular
function
associ
receptor
would
seriou
consequ
host
organ
virus
adsorpt
cell
use
differ
surfac
molecul
call
coreceptor
origin
thought
uniqu
receptor
human
immunodefici
viru
type
later
coreceptor
normal
function
chemokin
receptor
discov
case
capsid
protein
role
adhes
cell
envelop
human
virus
use
two
basic
mechan
entri
cell
mechan
involv
fusion
viral
envelop
cellular
membran
result
case
releas
free
nucleocapsid
cytoplasm
paramyxovirus
retrovirus
herpesvirus
enter
cell
process
call
direct
fusion
direct
fusion
spike
present
envelop
virus
promot
fusion
viral
membran
plasma
membran
cell
result
releas
nucleocapsid
directli
cytoplasm
due
fact
viral
envelop
becom
incorpor
plasma
membran
infect
cell
still
express
fusion
protein
infect
cell
tendenc
fuse
uninfect
cell
remain
envelop
anim
virus
orthomyxovirus
influenza
virus
togavirus
rubella
viru
rhabdovirus
rabi
coronavirus
enter
cell
cellular
mechan
call
receptormedi
endocytosi
viropexi
viropexi
virus
adsorb
cell
multipl
interact
viru
attach
protein
host
cell
molecul
thu
facilit
plasma
membran
surround
host
cell
molecul
pinch
cellular
membran
fusion
enclos
virion
cytoplasm
endosom
vesicl
acidifi
normal
cellular
process
endosom
vesicl
nucleocapsid
surround
two
membran
viral
envelop
newli
acquir
endosom
membran
low
ph
endosom
lead
conform
chang
viral
spike
protein
result
fusion
two
membran
releas
nucleocapsid
cytoplasm
nonenvelop
virus
enter
cell
viropexi
lowph
endosom
vesicl
viral
capsid
protein
nonenvelop
virus
expos
hydrophob
domain
result
bind
virion
membran
releas
nucleic
acid
genom
cytoplasm
case
virion
may
escap
endosom
vesicl
simpl
stimul
lysi
vesicl
step
potenti
target
antivir
therapi
drug
develop
bind
capsid
picornavirus
prevent
releas
viru
particl
endosom
except
influenza
virus
retrovirus
rna
virus
replic
cytoplasm
retrovirus
influenza
virus
dna
virus
except
poxvirus
replic
nucleu
need
movement
cytoplasm
nucleu
larger
dna
virus
herp
virus
adenovirus
uncoat
level
core
entri
nucleu
wherea
smaller
dna
virus
parvovirus
papovavirus
enter
nucleu
intact
nuclear
pore
subsequ
uncoat
insid
largest
human
virus
poxvirus
accomplish
entir
replic
cycl
cytoplasm
infect
cell
key
step
everi
viral
infect
product
virusspecif
mrna
direct
synthesi
viral
protein
structur
protein
virion
enzym
special
protein
requir
genom
replic
gene
express
viru
assembl
releas
viral
mrna
dna
virus
synthes
host
dnadepend
rna
polymeras
rna
polymeras
ii
singl
strand
rna
virus
picornavirus
togavirus
coronavirus
possess
posit
singlestrand
rna
use
directli
mrna
process
translat
immedi
entri
cytoplasm
cell
one
viral
protein
rna
depend
rna
polymeras
requir
synthesi
new
mrna
sinc
cellular
machineri
use
either
singleor
doublestrand
rna
templat
synthes
mrna
therefor
poxvirus
virus
use
rna
templat
make
mrna
must
provid
transcript
machineri
produc
viral
mrna
begin
infect
process
later
time
cours
infect
special
enzymat
machineri
viru
requir
present
initi
cell
obtain
among
protein
translat
mrna
molecul
parvovirus
singlestrand
dna
genom
rna
polymeras
cell
requir
doublestrand
dna
templat
virus
need
carri
special
enzym
virion
host
cell
dna
polymeras
convert
genom
doublestrand
dna
howev
product
mrna
picornavirus
requir
synthesi
intermedi
negativestrand
rna
templat
requir
translat
product
enzym
call
rnadepend
rna
polymeras
earli
cours
infect
retrovirus
special
form
posit
singlestrand
rna
virus
although
genom
retrovirus
polar
mrna
could
serv
mrna
earli
infect
rna
genom
virus
copi
neg
dna
strand
revers
transcriptas
enzym
alway
present
insid
virion
newli
synthes
neg
dna
strand
subsequ
convert
enzym
doublestrand
dna
accompani
degrad
origin
genom
rna
rnase
h
activ
revers
transcriptas
dna
made
activ
revers
transcriptas
integr
host
cell
dna
transcrib
host
rna
polymeras
order
complet
replic
cycl
produc
viral
mrna
replic
hepat
b
dna
genom
mechanist
similar
replic
process
retroviru
case
hepat
b
viru
viral
dna
templat
process
transcript
product
singlestrand
rna
turn
revers
transcrib
produc
progeni
viral
dna
becom
part
new
virion
enzym
accessori
protein
requir
replic
dna
eukaryot
cell
present
phase
cell
cycl
locat
nucleu
extent
virus
use
cell
replic
machineri
depend
proteincod
potenti
thu
size
genom
smallest
dna
virus
parvovirus
complet
depend
host
machineri
mean
replic
divid
cell
normal
phase
cell
cycl
occur
viral
dna
replic
togeth
cellular
dna
larg
dna
virus
rel
independ
cellular
function
replic
cytoplasm
code
almost
enzym
protein
requir
replic
dna
remaind
dna
virus
partial
depend
host
machineri
small
dna
human
virus
polyomavirus
papillomavirus
code
protein
involv
initi
synthesi
origin
host
machineri
accomplish
remaind
replic
process
extent
complex
adenovirus
herpesvirus
addit
provid
originspecif
protein
also
encod
dna
polymeras
accessori
protein
requir
dna
replic
fact
herpesvirus
encod
dna
polymeras
key
point
exploit
creation
antivir
therapeut
certain
antivir
drug
acyclovir
acycloguanosin
preferenti
kill
cell
infect
herp
virus
viral
thymidin
kinas
unlik
cellular
counterpart
phosphoryl
nucleosid
analog
phosphoryl
nucleosid
analogu
inhibit
dna
synthesi
dna
polymeras
incorpor
dna
host
cell
enzym
discrimin
better
host
nucleosid
acyclovir
analog
fail
phosphoryl
acyclovir
analogu
inhibit
synthesi
cellular
dna
fail
accordingli
acyclovir
kill
uninfect
cell
similar
principl
appli
chaintermin
drug
zidovudin
dideoxyinosin
phosphoryl
cellular
kinas
target
revers
transcriptas
also
inhibit
cellular
dna
polymeras
extent
replic
rna
virus
mostli
take
place
cytoplasm
moreov
cell
rna
polymeras
enzym
necessari
copi
rna
templat
rnabas
rna
transcript
replic
accordingli
rna
virus
need
encod
transcriptas
polymeras
requir
transcript
also
must
provid
polymeras
requir
duplic
rna
genom
daughter
rna
genom
furthermor
except
case
picornavirus
transcript
replic
synonym
rna
virus
must
tempor
function
separ
transcript
replic
replic
begin
templat
use
synthes
fulllength
strand
replic
two
mechan
separ
process
transcript
replic
case
transcript
restrict
subvir
particl
util
transcriptas
transport
cell
within
virion
case
replic
process
either
involv
function
distinct
rna
polymeras
depend
presenc
accessori
protein
specif
viru
direct
synthesi
fulllength
copi
templat
process
insert
viral
genom
capsid
protein
call
assembl
capsid
four
gener
principl
govern
construct
capsid
nucleocapsid
process
gener
involv
selfassembl
compon
assembl
stepwis
order
individu
protein
structur
subunit
protom
usual
preform
capsomer
prepar
final
assembl
process
assembl
often
initi
particular
locu
genom
call
packag
site
virus
may
leav
cell
sever
mechan
via
bud
apoptosi
exocytosi
induct
cell
lysi
bud
cell
membran
mechan
effect
virus
need
envelop
prior
bud
viru
put
receptor
onto
surfac
cell
form
envelop
viral
receptor
alreadi
process
slowli
use
cell
membran
eventu
lead
demis
cell
also
antivir
respons
abl
detect
virusinfect
cell
viru
infect
anim
cell
program
autodestruct
besid
virus
could
also
role
forc
cell
undergo
apoptosi
thu
releas
progeni
extracellular
space
possibl
virus
mostli
nonenvelop
leav
cell
exocytosi
newli
synthes
viral
particl
use
host
cell
transport
system
vesicl
contain
viru
particl
carri
cell
membran
releas
extracellular
space
cell
lysi
also
accompani
releas
viral
particl
step
viral
replic
uniqu
virus
potenti
target
point
antivir
agent
among
uniqu
process
attach
penetr
uncoat
rnadirect
dna
synthesi
revers
transcript
rnadirect
rna
synthesi
assembl
releas
virion
gener
overview
point
action
antivir
agent
shown
fig
attach
viru
host
cell
mediat
specif
interact
certain
molecul
virus
host
cell
antibodi
bind
viru
extracellular
space
thu
prevent
attach
cell
howev
although
therapi
antibodi
use
prophylaxi
minim
effect
treatment
amantadin
rimantadin
symmetr
amin
inhibit
viral
uncoat
show
activ
influenza
use
either
prophylaxi
therapi
sinc
rate
resist
amantadinerimantadin
extrem
increas
longer
routin
recommend
amantadin
rimantadin
avail
oral
prepar
major
toxic
exert
cn
select
inhibitor
neuraminidas
influenza
b
virus
oseltamivir
zanamivir
role
neuraminidas
cleavag
termin
sialic
acid
glycoconjug
allow
releas
viru
infect
cell
zanamivir
given
inhal
oseltamivir
phosphat
oral
prodrug
oseltamivir
drug
compar
zanamivir
antineuraminidas
activ
antivir
agent
current
use
nucleosid
analog
activ
viru
specif
nucleic
acid
polymeras
revers
transcriptas
much
less
activ
analog
host
enzym
agent
role
termin
nucleic
acid
chain
incorpor
nucleic
acid
idoxuridin
halogen
pyrimidin
incorpor
dna
place
thymidin
reaction
block
nucleic
acid
synthesi
produc
nonfunct
molecul
cellular
thymidin
kinas
phosphoryl
idoxuridin
make
activ
compound
inhibit
viral
cellular
dna
polymeras
result
host
toxic
exclud
system
administr
human
idoxuridin
use
topic
effect
treatment
herpet
infect
cornea
kerat
trifluorothymidin
relat
pyrimidin
analog
effect
treat
herpet
corneal
infect
includ
fail
respond
idoxuridin
acyclovir
differ
nucleosid
guanosin
acycl
hydroxyethoxymethyl
side
chain
acyclovir
activ
need
phosphoryl
viral
thymidin
kinas
sinc
acyclovir
phosphoryl
activ
uninfect
host
cell
drug
essenti
nontox
viral
thymidin
kinas
catalyz
phosphoryl
acyclovir
monophosph
wherea
hostcel
enzym
continu
phosphoril
diphosph
final
triphosph
acyclovir
triphosph
compet
guanosin
triphosph
inhibit
function
viral
encod
dna
polymeras
final
inhibit
viral
replic
select
minim
toxic
acyclovir
due
greater
affin
viral
dna
polymeras
cellular
dna
polymeras
second
mechan
viral
inhibit
come
incorpor
acyclovir
triphosph
grow
viral
dna
chain
group
acyclovir
serv
attach
site
addit
nucleotid
thu
result
acyclovir
incorpor
termin
chain
growth
activ
acyclovir
herp
virus
directli
correl
capac
viru
induc
thymidin
kinas
suscept
strain
herp
simplex
viru
type
contain
activ
thymidin
kinas
readili
inhibit
acyclovir
cytomegaloviru
cmv
induc
littl
phosphoril
acyclovir
inhibit
drug
varicellazost
epsteinbarr
virus
two
extrem
term
thymidin
kinas
induct
suscept
acyclovir
resist
strain
hsv
recov
immunodefici
patient
includ
patient
acquir
immunodefici
syndrom
aid
rare
immunocompet
patient
even
year
drug
exposur
case
resist
result
mutat
viral
thymidin
kinas
gene
make
inact
phosphoryl
resist
may
also
result
mutat
viral
dna
polymeras
acyclovir
avail
three
applic
form
topic
oral
parenter
oral
form
low
bioavail
achiev
concentr
blood
inhibit
hsv
lesser
extent
varicellazost
viru
vzv
intraven
acyclovir
use
seriou
hsv
infect
congenit
infect
enceph
well
vzv
infect
immunocompromis
patient
dosag
acyclovir
must
reduc
patient
renal
failur
given
fact
acyclovir
excret
kidney
central
nervou
system
toxic
renal
toxic
report
patient
treat
prolong
high
intraven
dose
acyclovir
induc
bone
marrow
toxic
even
patient
hematopoiet
disord
acyclovir
effect
treatment
primari
hsv
mucocutan
infect
sever
recurr
immunocompromis
patient
agent
use
neonat
herp
enceph
infect
immunocompromis
patient
varicella
older
children
adult
acyclovir
benefici
herp
zoster
elderli
patient
patient
eye
infect
patient
frequent
sever
genit
herp
oral
form
effect
prevent
recurr
minim
effici
treatment
recurr
genit
labial
herp
otherwis
healthi
person
valacyclovir
prodrug
acyclovir
show
better
absorpt
thu
use
lower
less
frequent
dosag
current
approv
therapi
hsv
vzv
infect
adjust
valacyclovir
dosag
necessari
patient
insuffici
renal
function
famciclovir
similar
structur
acyclovir
also
requir
phosphoryl
differ
slightli
mode
action
absorpt
famciclovir
convert
penciclovir
activ
moieti
inhibit
viral
dna
polymeras
irrevers
termin
dna
replic
famciclovir
current
approv
treatment
hsv
vzv
infect
penciclovir
approv
topic
treatment
recurr
herp
labiali
ganciclovir
nucleosid
analog
guanosin
differ
acyclovir
singl
carboxyl
side
chain
make
approxim
time
activ
cmv
compar
acyclovir
acyclovir
low
activ
cmv
cmv
carri
gene
thymidin
kinas
adequ
phosphoryl
acyclovir
cmvinfect
cell
lack
howev
ganciclovir
activ
cmv
requir
thymidin
kinas
phosphoryl
rather
anoth
phosphoryl
enzym
encod
viral
genom
present
cmvinfect
cell
capabl
phosphoryl
ganciclovir
convert
monophosph
later
cellular
enzym
convert
activ
compound
ganciclovir
triphosph
inhibit
viral
dna
polymeras
oral
ganciclovir
avail
inferior
intraven
form
oral
valganciclovir
prodrug
ganciclovir
improv
bioavail
equival
intraven
form
toxic
especi
neutropenia
frequent
limit
therapi
thrombocytopenia
occur
approxim
patient
ganciclovir
valganciclovir
indic
prevent
treatment
activ
cmv
infect
immunodefici
patient
herpesvirus
particularli
vzv
also
suscept
sever
month
continu
ganciclovir
therapi
use
control
cmv
infect
patient
aid
excret
resist
strain
cmv
almost
isol
mutat
found
phosphoryl
gene
lesser
number
mutat
may
also
found
viral
dna
polymeras
ganciclovir
resist
note
transplant
recipi
especi
requir
prolong
prophylaxi
treatment
resist
common
patient
lung
liver
transplant
known
nucleotid
analog
cidofovir
cidofovir
phosphon
group
attach
molecul
appear
cell
nucleosid
monophosph
fact
nucleotid
activ
compound
produc
cellular
enzym
add
two
phosphat
group
monophosph
form
form
triphosph
drug
inhibit
viral
cellular
nucleic
acid
polymeras
howev
greater
select
toward
cidofovir
exert
viral
enzym
drug
select
effect
nucleotid
analog
requir
phosphoryl
activ
viralencod
enzym
remain
activ
virus
resist
due
mutat
codon
enzym
exampl
mutant
cmv
resist
cidofovir
develop
mutat
viral
dna
polymeras
addit
featur
cidofovir
prolong
halflif
result
slow
clearanc
kidney
cidofovir
approv
intraven
therapi
cmv
retin
given
frequent
everi
week
mainten
treatment
nephrotox
seriou
complic
cidofovir
treatment
patient
must
monitor
care
evid
renal
impair
lamivudin
first
clinic
employ
inhibitor
hepat
b
dna
polymeras
follow
usual
replac
similar
molecul
adefovir
entecavir
telbivudin
tenofovir
last
develop
less
resist
entecavir
tenofovir
becom
prefer
agent
monotherapi
due
potenc
low
rate
resist
develop
polymeras
inhibitor
use
monotherapi
due
eas
resist
may
develop
foscarnet
pyrophosph
analog
inhibit
viral
dna
polymeras
block
pyrophosphatebind
site
viral
dna
polymeras
prevent
cleavag
pyrophosph
deoxyadenosin
triphosph
contrast
nucleosid
acyclovir
ganciclovir
foscarnet
requir
phosphoryl
activ
inhibitor
viral
dna
polymeras
biochem
characterist
foscarnet
especi
import
regard
viral
resist
viral
resist
nucleosid
analog
caus
mutat
reduc
elimin
phosphoryl
drug
virusinfect
cell
thu
foscarnet
usual
use
treat
patient
ganciclovirresist
cmv
acyclovirresist
hsv
multipl
metabol
abnorm
occur
evid
toxic
excret
entir
renal
without
hepat
compon
dosag
must
decreas
patient
impair
renal
function
interferon
protein
synthes
variou
host
cell
encod
host
gene
respons
doublestrand
rna
dsrna
interferon
circul
role
protect
uninfect
cell
inhibit
viral
protein
synthesi
recombin
dna
techniqu
allow
rel
inexpens
largescal
product
interferon
bacteria
yeast
interferon
benefici
treatment
chronic
activ
hepat
b
c
infect
although
efficaci
often
transient
combin
lamivudin
famciclovir
certain
nucleotid
evalu
treatment
hepat
b
pegyl
therapeut
procedur
treatment
chronic
hepat
c
diseas
treatment
chronic
c
hepat
last
month
combin
ribavirin
usual
produc
improv
result
topic
intralesion
interferon
applic
benefici
treatment
human
papilloma
viru
infect
parenter
use
accompani
sever
system
toxic
eg
fever
malais
probabl
due
effect
hostcel
protein
synthesi
ribavirin
analog
nucleosid
guanosin
differ
guanosin
base
ring
incomplet
open
like
nucleosid
analog
ribavirin
must
phosphoryl
mono
di
triphosph
form
reach
activ
form
sinc
step
phosphoryl
ribavirin
mediat
cellular
enzym
risk
toxic
increas
ribavirin
activ
broad
rang
virus
vitro
vivo
activ
limit
mechan
antivir
effect
ribavirin
clear
case
acyclovir
ribavirin
inhibit
rna
polymeras
also
inhibit
inosin
monophosph
dehydrogenas
enzym
import
synthet
pathway
guanosin
interfer
guanyl
methyl
nucleic
acid
ribavirin
decreas
synthesi
mrna
cap
administr
via
aerosol
enabl
ribavirin
reach
time
greater
concentr
respiratori
secret
necessari
inhibit
respiratori
syncyti
viru
rsv
replic
significantli
higher
achiev
oral
administr
problem
associ
usag
aerosol
ribavirin
includ
precipit
drug
tube
use
administr
exposur
healthcar
personnel
thu
use
rsv
infect
gener
recommend
oral
intraven
form
use
patient
lassa
fever
infect
arenavirus
oral
form
ribavirin
activ
hepat
c
viru
combin
pegifn
combin
main
use
present
preclin
studi
ribavirin
show
teratogen
mutagen
gonadotox
effect
wherea
revers
anemia
associ
oral
administr
fomivirsen
first
antisens
compound
approv
use
human
infect
synthet
oligonucleotid
complementari
sequenc
cmv
messeng
rna
mrna
therebi
inhibit
code
major
immedi
earli
transcript
unit
cmv
encod
sever
protein
respons
regul
viral
gene
express
fomivirsen
probabl
inhibit
product
protein
oligonucleotid
phosphorothio
linkag
replac
usual
nucleas
formivirsen
fomivirsen
exert
greater
antivir
activ
ganciclovir
molar
basi
approv
local
intravitr
therapi
cmv
retin
patient
fail
therapi
enfuvirtid
synthet
peptid
inhibit
fusion
cell
oral
form
usual
reserv
patient
fail
therapi
maraviroc
interfer
attach
hiv
receptor
thu
block
predomin
rout
hiv
entri
cell
resist
may
develop
viru
adapt
anoth
receptor
zidovudin
nucleosid
analog
thymidin
inhibit
revers
transcriptas
hiv
mention
nucleosid
zidovudin
must
phosphoryl
order
activ
phosphoryl
zidovudin
carri
host
cell
enzym
basi
rel
select
therapeut
effect
zidovudin
hiv
revers
transcriptas
time
sensit
zidovudin
host
cell
dna
polymeras
nonetheless
toxic
frequent
occur
zidovudin
first
use
treatment
hiv
infect
recommend
use
combin
inhibitor
hiv
replic
lamivudin
proteas
inhibitor
toxic
zidovudin
includ
malais
nausea
bone
marrow
toxic
toxic
hematopoiet
compon
may
notic
usual
revers
discontinu
drug
dose
reduct
resist
associ
one
mutat
hiv
revers
transcriptas
gene
seri
oral
compound
similar
zidovudin
develop
use
combin
hiv
antivir
although
similar
mechan
action
side
effect
may
differ
compound
includ
didanosin
zalcitabin
seriou
advers
reaction
treatment
includ
peripher
neuropathi
either
didanosin
zalcitabin
pancreat
didanosin
side
effect
dose
relat
anoth
nucleosid
analog
inhibit
hiv
replic
stavudin
stavudin
also
termin
growth
viral
nucleic
acid
chain
stavudin
well
absorb
high
bioavail
advers
effect
therapeut
includ
headach
nausea
vomit
asthenia
confus
elev
serum
transaminas
creatinin
kinas
pain
sensori
peripher
neuropathi
appear
doserel
may
occur
stavudin
use
combin
antihiv
agent
lamivudin
anoth
oral
nucleosid
revers
transcriptas
inhibitor
therapeut
safe
usual
welltoler
agent
lamivudin
use
combin
zidovudin
nucleosid
analog
lamivudin
suppress
develop
persist
mutat
lead
zidovudin
resist
newer
oral
nucleosid
revers
transcriptas
inhibitor
abacavir
emtricitabin
like
discuss
earlier
use
combin
class
hiv
antivir
oral
compound
nucleosid
analog
also
inhibit
hiv
revers
transcriptas
sever
compound
nevirapin
delavirdin
efavirenz
etravirin
evalu
alon
combin
nucleosid
collect
refer
nonnucleosid
revers
transcriptas
inhibitor
nnrti
compound
activ
hiv
requir
cellular
enzym
phosphoryl
bind
essenti
site
revers
transcriptas
crossresist
occur
nucleosid
rt
inhibitor
nnrti
occur
one
nnrti
anoth
compound
inhibit
human
dna
polymeras
cytotox
concentr
requir
effect
antivir
activ
therefor
rel
nontox
unfortun
drug
resist
readili
emerg
even
singl
passag
viru
presenc
drug
vitro
vivo
thu
nnrti
use
combin
regimen
drug
activ
hiv
proteas
inhibitor
block
action
viral
encod
enzym
proteas
cleav
polyprotein
produc
final
viral
protein
inhibit
enzym
lead
blockag
viral
assembl
releas
proteas
inhibitor
potent
inhibitor
hiv
replic
vitro
vivo
mostli
combin
antiretrovir
agent
drug
requir
intracellular
phosphoryl
activ
late
saquinavir
first
proteas
inhibitor
receiv
approv
ritonavir
indinavir
nelfinavir
darunavir
fosamprenavir
tipranavir
potent
proteas
inhibitor
sinc
releas
drug
may
caus
hepatotox
agent
inhibit
result
import
drug
interact
drug
resist
proteas
inhibitor
develop
agent
use
alon
without
antihiv
drug
lopinavir
proteas
inhibitor
market
combin
ritonavir
atazanavir
anoth
proteas
inhibitor
usual
prescrib
ritonavir
increas
serum
concentr
atazanavir
hiv
integras
aid
insert
viral
dna
hostcel
dna
occur
viral
revers
transcriptas
rnadnadepend
dna
polymeras
produc
doublestrand
viral
dna
step
key
cell
becom
perman
carrier
two
integras
inhibitor
raltegravir
elvitegravir
approv
use
usual
use
treatment
experienc
patient
combin
class
antiretrovir
sinc
viral
genom
viral
replic
cycl
mechan
action
avail
antivir
agent
extens
studi
understand
resist
antivir
drug
evolv
becom
clear
central
role
resist
antivir
agent
gene
mutat
exampl
mutat
viralinduc
enzym
catalyz
phosphoryl
nucleosid
common
mechan
resist
nucleosid
acyclovir
ganciclovir
herp
virus
probabl
occurr
resist
mutant
result
least
four
factor
rate
viral
replicationhigh
rate
replic
associ
higher
rate
spontan
mutat
select
pressur
drugth
greater
drug
exposur
rapid
emerg
resist
mutant
point
rate
viral
mutationsth
rate
mutat
differ
among
differ
virus
gener
singlestrand
rna
virus
hiv
influenza
rapid
rate
mutat
doublestrand
dna
virus
hsv
rate
mutat
differ
viral
gene
nanoparticl
emerg
last
year
altern
materi
advanc
diagnost
therapeut
applic
medicin
compar
molecular
medicin
nanoparticl
offer
mani
advantag
bioavail
biodistribut
therapeut
agent
first
remark
properti
nanoparticl
superior
vivo
retent
decreas
enzymat
degrad
sequestr
phagocyt
reticuloendotheli
system
mostli
attribut
immunochem
inert
surfac
contact
biolog
environ
increas
deposit
diseas
site
via
compromis
vasculatur
phenomenon
call
enhanc
permeabl
retent
effect
also
contribut
improv
deposit
diseas
site
efficaci
differ
nanoparticl
propos
year
carrier
antivir
agent
mostli
consid
nanoparticl
shown
fig
first
commerci
nanostructur
liposom
use
drug
deliveri
system
first
introduc
liposom
spheric
vesicular
system
consist
least
one
lipid
bilay
lipid
layer
mostli
natur
synthet
phospholipid
often
phosphatidylcholin
insid
lipid
layer
aqueou
core
main
type
liposom
small
unilamellar
vesicl
larg
unilamellar
vesicl
multilamellar
vesicl
depend
method
use
prepar
liposom
vari
size
nm
hydrophil
therapeut
incorpor
liposom
insid
aqueou
core
wherea
lipophil
therapeut
insert
lipid
effici
incorpor
therapeut
liposom
depend
size
liposom
hydrophob
charg
surfac
membran
fluiditi
characterist
liposom
also
influenc
vitro
stabil
biodistribut
appli
therapeut
phagocit
cell
spleen
rapidli
recogn
liposom
intraven
applic
intern
reduct
engulf
liposom
phagocyt
achiev
chemic
modif
liposom
poli
ethylen
glycol
peg
unit
howev
surfac
liposom
modifi
way
increas
recognit
subsequ
endocytosi
macrophag
cell
innat
immun
system
sinc
hiv
resid
macrophag
liposom
mainli
studi
carrier
antihiv
drug
deliveri
hiv
vaccin
well
sirna
also
certain
disadvantag
carrier
viral
agent
poor
stabil
vitro
well
vivo
low
effici
incorpor
lipid
bilay
aqueou
core
high
cost
product
liposom
deliveri
system
construct
acyclovir
local
treatment
genit
herp
recurr
genit
herp
liposom
also
use
carrier
topic
applic
acyclovir
also
antisens
oligonucleotid
intravitr
administr
treatment
ocular
cmv
infect
necessari
corneal
penetr
acyclovir
vitro
good
corneal
absorpt
vivo
achiev
construct
acyclovir
load
posit
charg
liposom
importantli
liposom
also
use
carrier
oral
administr
anoth
form
vesicl
noisom
design
drug
deliveri
niosom
vesicl
similar
liposom
instead
lipid
niosom
form
nonion
surfact
appear
niosom
better
carrier
acyclovir
compar
liposom
due
superior
load
slower
releas
drug
niosom
also
found
improv
oral
bioavail
acyclovir
compar
liposom
micel
amphiphil
colloid
structur
particl
diamet
nm
rang
micel
consist
molecul
contain
two
complet
differ
region
opposit
affin
water
amphiphil
molecul
form
micel
associ
certain
temperatur
appropri
concentr
core
micel
form
hydrophob
fragment
amphiphil
molecul
wherea
micel
shell
consist
hydrophil
fragment
micellar
molecul
micellar
amphiphil
molecul
low
concentr
exist
separ
aqueou
medium
aggreg
micellar
molecul
take
place
concentr
increas
aggreg
micellar
molecul
happen
within
limit
concentr
interv
critic
micel
concentr
concentr
monomer
micellar
amphiphil
aggreg
begin
micel
appear
critic
micel
temperatur
temperatur
aggreg
appear
micellar
molecul
exist
monom
aggreg
amphiphil
molecul
format
micel
happen
remov
hydrophob
fragment
micellar
molecul
aqueou
environ
reconstitut
hydrogen
bond
water
lead
decreas
free
energi
system
micel
use
carrier
therapeut
aqueou
media
carri
lipophil
drug
within
core
micel
surfac
bind
polar
molecul
improv
aqueou
solubl
thu
better
intestin
permeabl
micel
achiev
format
polymer
micel
polymer
micel
form
amphiphil
block
copolym
compar
convent
micel
show
greater
stabil
vivo
virus
use
lectin
receptor
host
cell
entri
cell
infect
cell
also
express
lectin
order
target
viral
reservoir
micel
consist
pegpolylactid
copolym
surfac
modifi
galactos
construct
sinc
galactos
residu
interact
lectin
microspher
spheric
microparticl
use
drug
carrier
size
microspher
micron
rang
microspher
mostli
form
biodegrad
polym
two
type
microspher
monolithictyp
matrixtyp
reservoirtyp
capsular
capsular
type
microspher
also
call
microcapsul
microspher
abl
incorpor
wide
rang
differ
drug
biocompat
prepar
biodegrad
particl
microspher
formul
biodegrad
particl
polyd
llactid
poli
llactidecoglycolid
encapsul
antivir
drug
acyclovir
propos
intraocular
administr
prolong
releas
acyclovir
achiev
encapsul
within
poli
llactidecoglycolid
enabl
reduct
dose
acyclovir
addit
vitamin
palmit
poli
llactidecoglycolid
microspher
acyclovir
increas
load
acyclovir
lead
prolong
vitro
releas
acyclovir
day
mani
attempt
increas
bioavail
acyclovir
oral
administr
mucoadhes
microspher
made
thiolat
chitosan
enhanc
retent
drug
upper
gastrointestin
tract
thu
increas
oral
bioavail
acyclovir
anoth
form
mucoadhes
microspher
encapsul
acyclovir
made
ethylcellulos
matrix
carpobol
lubrizol
wicklif
oh
usa
mucoadhes
polym
also
prolong
resid
acyclovir
gastrointestin
tract
rat
improv
oral
bioavail
microspher
encapsul
interferon
alpha
design
oral
deliveri
microspher
contain
crosslink
malonylchitosan
encapsul
acyclovir
topic
prepar
design
order
increas
concentr
drug
basal
layer
epidermi
also
attempt
use
microspher
deliveri
system
vaccin
order
sustain
immunolog
challeng
dendrim
polymer
branch
nanostructur
inimit
perfect
structur
featur
dendrim
central
core
branch
eman
thu
form
threedimension
treelik
structur
three
main
portion
core
inner
outer
shell
portion
differ
properti
solubl
bind
ligand
size
dendrim
rel
small
diamet
lower
nm
bind
differ
ligand
make
attract
drug
deliveri
precis
biolog
physicochem
characterist
dendrim
achiev
usag
differ
type
polym
function
group
also
singl
dendrim
conjug
differ
drug
ligand
dendrim
use
deliveri
dna
sirna
antivir
therapeut
wide
known
dendrim
use
antivir
therapi
vivagel
formul
mucoadhes
gel
vivagel
first
topic
nanomicrobicid
form
dival
benzhydylamin
amid
llysin
contain
sodium
carboxymethoxi
termin
anion
function
group
enabl
prolong
durat
antivir
activ
nanoparticl
small
solid
colloid
polymer
particl
diamet
lower
structur
nanoparticl
similar
microspher
matrixlik
nanoparticl
capsulelik
nanocapsel
differ
materi
protein
lipid
inorgan
materi
use
creation
nanoparticl
howev
polymer
nanoparticl
mostli
made
natur
synthet
biocompat
andor
biodegrad
polym
poli
lacticcoglycol
acid
poli
lactic
acid
algin
cyclodextrin
hyaluron
acid
poli
glycol
acid
polycaprolacton
usag
polym
maxim
tissu
compat
reduc
cytotox
effect
within
nanoparticl
activ
molecul
dissolv
encapsul
adsorb
conjug
sinc
size
small
nanoparticl
applic
intraven
describ
liposom
phagocytosi
nanoparticl
avoid
addit
hydrophil
compon
like
peg
chain
surfac
pegyl
nanoparticl
often
label
stealth
nanoparticl
differ
polymer
nanoparticl
made
polylactid
poli
isobutyl
cyanoacryl
poli
ethylacryl
methacryl
chlorotrimethyl
methacryl
incorpor
acyclovir
increas
activ
oral
bioavail
acyclovir
lipid
nanoparticl
made
lipid
solid
bodi
temperatur
also
use
deliveri
therapeut
agent
two
type
lipid
nanoparticl
solid
lipid
nanoparticl
nanostructur
lipid
carrier
solid
lipid
nanoparticl
stabl
solid
state
abil
protect
ingredi
labil
chemic
properti
modul
releas
drug
nanostructur
lipid
carrier
contain
solid
lipid
matrix
partli
liquid
lipid
phase
content
lipid
nanoparticl
advantag
comparison
liposom
convent
emuls
due
abil
overcom
problem
stabil
membran
associ
drug
leach
lipid
nanoparticl
contain
acyclovir
vitro
show
greater
activ
free
drug
also
lipid
nanoparticl
incorpor
adefovir
dipivoxil
prepar
therapi
hepat
b
infect
protein
nanoparticl
prepar
albumin
polym
also
develop
deliveri
system
ganciclovir
antisens
oligonucleotid
therapi
cytomegaloviru
infect
cation
gelatin
nanoparticl
increas
immunostimulatori
effect
cpg
oligonucleotid
sever
studi
show
antivir
potenti
silver
nanoparticl
ag
ion
releas
silver
nanoparticl
interact
directli
biomolecul
contain
phosphoru
sulfur
includ
protein
dna
rna
seem
silver
nanoparticl
interfer
sever
stage
viral
replic
cycl
includ
attach
virus
cell
membran
entri
cell
dna
rna
replic
protein
synthesi
paul
ehrlich
postul
magic
bullet
theori
progress
synthesi
novel
nanomateri
enabl
sitespecif
drug
deliveri
three
differ
strategi
drug
target
precis
local
direct
inject
drug
precis
site
passiv
target
activ
target
passiv
target
drug
reach
specif
organ
tissu
carri
nanoparticul
specif
intrins
properti
differ
size
nanoparticl
lipophil
surfac
nanoparticul
carrier
incorpor
drug
target
tissu
small
size
surfac
characterist
nanoparticl
enabl
take
lymphat
tissu
gut
specif
peyer
patch
contain
cell
oral
administr
cell
take
nanoparticl
sizedepend
manner
lymph
vessel
transport
lymphocyt
kind
absorpt
drug
oral
administr
provid
bypass
system
metabol
drug
liver
accumul
nanoparticl
lymph
node
permit
target
lymphat
system
sinc
nanoparticl
accumul
lymphat
tissu
could
use
target
viral
reservoir
retain
within
compart
lymphat
target
nanoparticl
inject
system
achiev
particl
appropri
size
enough
small
dispers
interstitium
around
inject
site
also
enough
larg
drain
lymph
vessel
optim
size
nanoparticl
rang
nm
besid
follow
interstiti
inject
hydrophil
nanoparticl
clear
rapidli
hydrophob
nanoparticl
activ
target
achiev
differ
strategi
mostli
surfac
modif
particular
via
specif
ligandreceptorlik
mechan
first
strategi
base
usag
monoclon
antibodi
specif
antigen
express
certain
cell
tissu
strategi
use
target
precis
tissu
intracellular
compart
usag
stimulisensit
nanocarri
stimulisensit
nanocarri
sensit
inher
stimuli
patholog
site
intracellular
organel
abnorm
temperatur
valu
ph
valu
sensit
extern
appli
stimuli
exampl
magnet
field
temperatur
ultrasound
intern
extern
stimuli
affect
nanoparticl
dissolv
modifi
guid
sensit
nanocarri
final
result
releas
carri
drug
precis
region
great
interest
field
therapeut
applic
phsensit
nanocarri
due
fact
envelop
virus
acid
environ
endosom
lumen
reject
envelop
thu
infect
cell
liposom
nanogel
polymer
micel
phsensit
carrier
promot
intracellular
releas
encapsul
drug
ph
chang
phsensit
carrier
stabl
physiolog
ph
level
acid
environ
lysosom
environ
becom
unstabl
releas
aqueou
content
intracellular
space
label
nanocarri
guid
extern
stimuli
exampl
magnet
field
applic
certain
temperatur
ultrasound
case
magnet
drug
deliveri
extern
magnet
stimulu
guid
microparticl
encapsul
drug
specifi
tissu
induc
accumul
carrier
target
organ
howev
releas
drug
carrier
passiv
process
depend
properti
microparticl
system
hand
usag
ultrasound
extern
stimuli
allow
activ
releas
drug
site
action
drug
target
use
surfacemodifi
nanocarri
strategi
permit
deliveri
organ
even
cell
level
target
macrophag
achiev
usag
polyhexylcyanoacryl
nanoparticl
diamet
approxim
nm
enhanc
uptak
nanoparticl
macrophag
enhanc
addit
target
moieti
nanoparticl
exampl
mannanco
nanoparticl
target
macrophag
exploit
presenc
receptor
mannos
macrophag
enter
macrophag
mannos
receptormedi
endocytosi
coupl
tat
peptid
surfac
nanoparticl
enabl
endosom
escap
nanoparticul
allow
control
intracellular
distribut
drug
import
therapeut
must
reach
cytosol
nucleu
infect
variou
human
cell
type
lymphocyt
monocytesmacrophag
dendrit
cell
langerhan
cell
microglia
howev
drastic
effect
hiv
infect
result
destruct
lymphocyt
play
central
role
capac
host
mount
effect
protect
immun
respons
wide
rang
infect
agent
hiv
infect
character
acut
phase
intens
viral
replic
dissemin
lymphoid
tissu
manifest
fluor
mononucleosislik
ill
follow
activ
innat
adapt
immun
respons
unabl
clear
highli
replic
mutat
viru
slow
viral
replic
immun
activ
continu
chronic
persist
asymptomat
phase
clinic
latenc
final
stage
infect
immunodefici
aid
opportunist
infect
result
mark
deplet
lymphocyt
hiv
envelop
viru
nm
diamet
contain
two
copi
rna
coat
nucleocapsid
protein
rnaprotein
complex
enclos
capsid
call
cover
membraneassoci
matrix
call
protein
viral
envelop
contain
two
viral
encod
glycoprotein
virion
core
also
contain
three
virusspecif
nonstructur
protein
enzym
essenti
viral
replic
revers
transcriptas
proteas
integras
need
attach
host
cell
critic
cell
fusion
process
hiv
adher
cell
express
molecul
molecul
bind
molecul
result
conform
chang
conform
chang
bind
second
cellular
molecul
chemokin
receptor
known
coreceptor
next
event
conform
chang
enabl
fusion
membran
deliveri
capsid
cytoplasm
virionassoci
rnadepend
dna
polymeras
revers
transcriptas
mediat
revers
transcript
rna
complementari
dna
dnadepend
dna
polymeras
activ
revers
transcriptas
enzym
mediat
convers
complementari
dna
doublestrand
dna
viral
rna
templat
remov
rnadna
hybrid
rnaas
h
activ
revers
transcriptas
enzym
newli
synthes
dna
integr
cellular
genom
later
transcrib
fulllength
viral
rna
also
number
splice
mrna
transcript
process
transcript
viral
dna
translat
mediat
cellular
enzym
synthes
viral
protein
togeth
newli
transcrib
viral
rna
transport
cell
membran
assembl
viru
particl
take
place
viru
bud
cellular
surfac
exit
extracellular
space
life
expect
individu
infect
hiv
significantli
improv
introduct
highli
activ
antiretrovir
therapi
haart
haart
therapeut
approach
includ
sever
antiretrovir
drug
differ
mechan
action
current
six
class
antiretrovir
agent
includ
nucleosid
analog
revers
transcriptas
inhibitor
nrti
nonnucleosid
analog
revers
transcriptas
inhibitor
nnrti
proteas
inhibitor
pi
fusion
inhibitor
enfuvirtid
antagonist
maraviroc
integras
inhibitor
raltegravir
elvitegravir
doluyegravir
howev
constant
emerg
drugresist
viral
strain
caus
need
develop
new
therapeut
approach
overcom
therapeut
select
low
efficaci
therapeut
use
treatment
hiv
infect
individu
differ
nanostructur
synthes
year
propos
prophylact
agent
hiv
first
attempt
use
nanoparticl
antivir
therapi
synthesi
silver
nanoparticl
potenti
control
hiv
infect
silver
nanoparticl
size
nm
establish
interact
hiv
although
mechan
action
silver
nanoparticl
sever
studi
indic
interact
glycoprotein
hiv
envelop
prevent
bind
fusion
cell
membran
thu
disabl
hiv
enter
suscept
cell
poli
pvp
coat
silver
nanoparticl
bind
residu
glycoprotein
thu
block
interact
viru
host
cell
sinc
antivir
effect
agnp
exert
high
concentr
pvpcoat
agnp
propos
potenti
topic
vagin
microbicid
prevent
transmiss
variou
differ
deliveri
system
target
hiv
infect
cell
explorednam
liposom
dendrim
biodegrad
nonbiodegrad
polym
recent
albumin
nanoparticl
incorpor
antiretrovir
therapeut
efavirenz
synthet
size
particl
nm
analysi
show
carrier
significantli
increas
deliveri
efavirenz
sever
tissu
compar
free
drug
anoth
approach
involv
viral
dna
code
gag
env
viral
glycoprotein
adsorb
surfac
cation
poli
lactidecoglycolid
nanoparticl
order
induc
adequ
immun
respons
hiv
antigen
polimer
nanoparticl
viral
dna
togeth
form
pathogenlik
nanoparticl
known
dermavir
sugar
residu
role
uptak
antigenpres
cell
present
surfac
dermavir
nanoparticl
role
nanoparticul
polym
insid
cell
protect
viral
dna
endosom
degrad
facilit
deliveri
dna
nucleu
requir
express
dnaencod
antigen
shown
gold
nanoparticl
also
could
role
inhibit
hiv
fusion
host
cell
howev
usag
gold
nanoparticl
follow
toxic
side
effect
relat
size
shape
charg
composit
surfac
function
nanoparticl
appropri
surfac
coat
also
enabl
better
select
target
intern
achiev
signific
reduct
gold
nanoparticl
toxic
advantag
nanostructur
construct
transform
biolog
inact
molecul
multival
conjug
enabl
effect
inhibit
fusion
hiv
envelop
human
cell
antagonist
unabl
bind
receptor
high
affin
conjug
gold
nanoparticl
multival
manner
transform
biolog
inact
therapeut
activ
molecul
allow
effect
hivfus
inhibit
also
dcsignmedi
hiv
transinfect
human
lymphocyt
prevent
gold
nanoparticl
coat
oligomannos
molecul
shown
recent
carbon
nanotub
advantag
nanoparticl
carbon
nanotub
abl
cross
cell
membran
deliv
therapeut
variou
type
cell
carboxyl
group
nanotub
allow
prolong
contact
therapeut
target
molecul
promot
electrostat
hydrogen
bond
interact
amino
acid
residu
revers
transcriptas
highli
hydrophil
dispers
carboxyl
multiwal
carbon
nanotub
incorpor
antiretrovir
drug
lamivudin
recent
synthes
antivir
potenti
report
hcv
infect
caus
acut
chronic
hepat
signific
percentag
hcv
infect
chronic
cours
lead
cirrhosi
hepat
insuffici
hepatocellular
carcinoma
sever
year
hcv
virion
nm
diamet
contain
simpl
posit
sens
singlestrand
rna
genom
enclos
icosahedr
capsid
lipidbilay
envelop
contain
two
virusspecif
glycoprotein
six
group
mani
differ
subgroup
hcv
identifi
base
phylogenet
analysi
hcv
strain
isol
mani
differ
region
world
therapeut
use
current
therapi
hcv
infect
mostli
target
hcv
proteas
hcv
proteas
inhibitor
given
alon
gener
viru
resist
quickli
approv
therapi
patient
hcv
genotyp
infect
hcv
proteas
inhibitor
boceprevir
telaprevir
combin
pegyl
ribavirin
howev
drugresist
mutant
strain
hcv
viru
continu
aris
induc
reduc
effici
current
therapeut
need
develop
new
drug
demonstr
hcv
multipl
strategi
escap
immun
respons
host
entri
cell
includ
spread
viru
cell
cell
evas
neutral
antibodi
consid
wellconserv
receptor
coreceptor
present
host
cell
promis
target
therapeut
effici
prevent
hcv
infect
independ
viru
genotyp
exampl
target
molecul
claudin
usag
small
compound
target
glycoprotein
hcv
envelop
thu
block
viral
entri
genotypespecif
usag
nanostructur
could
altern
approach
therapi
hcv
infect
potenti
lipid
nanosom
cation
liposom
incorpor
sirna
inhibit
express
hcv
gene
proven
vivo
shown
altern
therapi
pegyl
targetspecif
hyaluron
acid
gold
conjug
hyaluron
acid
gold
conjug
significantli
enhanc
express
synthetas
liver
tissu
known
synthetas
role
innat
immun
viral
infect
rnase
activ
dextranco
magnet
iron
oxid
nanoparticl
conjug
synthet
dnazym
induc
knockdown
hcv
gene
encod
helicas
proteas
essenti
viru
replic
dextranco
magnet
iron
oxid
nanoparticl
accumul
primarili
liver
great
potenti
applic
antihcv
drug
recent
shown
boronicacid
modifi
nanostructur
inhibit
entri
hcv
hepatocyt
among
molecul
report
inhibit
hcv
entri
hepatocyt
variou
glycanrecogn
protein
lectin
lectin
select
interact
glycan
present
surfac
virus
shown
lectin
cyanovirinn
griffithsin
great
potenti
interact
highmannos
glycoprotein
surfac
hcv
envelop
reduc
contact
virus
host
cell
entri
hcv
cell
socal
pseudolectin
boron
acidbas
compound
much
simpler
structur
natur
lectin
access
synthet
mani
advantag
boron
acidbas
pseudolectin
natur
counterpart
interact
stabl
less
expens
produc
purifi
exert
mitogen
stimul
affin
lectin
appropri
glycan
significantli
increas
multipl
copi
synthet
lectin
eg
boron
acid
deriv
attach
onto
polymer
nanoparticl
besid
boron
acid
base
pseudolectin
mani
pseudolectin
investig
possibl
therapeut
hcv
includ
silica
diamond
iron
deriv
nanoparticl
howev
nanostructur
moder
maxim
inhibit
potenti
major
obstacl
develop
inhibitor
viral
entri
power
inhibitor
hcv
entri
amphiphil
boron
acid
moieti
insert
lipid
nanocapsul
herp
simplex
virus
ubiquit
exist
throughout
human
histori
initi
lytic
infect
latent
infect
establish
latent
infect
persist
life
host
two
type
hsv
type
type
infect
around
adult
worldwid
mainli
associ
infect
face
central
nervou
system
mainli
caus
infect
anogenit
area
infect
immunodefici
person
life
threaten
hsv
envelop
viru
central
core
linear
doublestrand
dna
viral
glycoprotein
hsv
lipid
bilay
envelop
entri
hsv
entri
host
cell
critic
step
pathogenes
viral
diseas
depend
bind
least
five
glycoprotein
viral
envelop
three
differ
receptor
membran
host
cell
herp
viru
entri
mediat
cell
surfac
glycosaminoglycan
preferenti
heparan
sulfat
import
step
hsv
attach
cell
irrevers
bind
two
viral
glycoprotein
cellular
heparan
sulfat
drastic
reduct
suscept
hsv
infect
notic
cell
defici
heparan
sulfat
indic
heparin
highli
attract
target
nanoparticl
conjug
antiheparan
sulfat
peptid
viral
dna
replic
mediat
viral
dna
polymeras
drug
use
therapi
hsv
infect
target
viral
dna
polymeras
guanosin
analogu
acyclovir
import
clinic
drug
prophylaxi
treatment
hsv
infect
although
acyclovir
consid
gold
standard
therapi
hsv
infect
extens
use
led
emerg
acyclovir
resist
hsv
strain
mostli
immunodefici
person
caus
intens
search
altern
drug
altern
therapi
block
viral
attach
host
cell
differ
level
recent
shown
structur
antihsv
activ
gold
silver
nanoparticl
sulfon
function
inhibit
viral
entri
prevent
viral
spread
cell
cell
gold
nanoparticl
mercaptoethanesulfon
nm
size
imit
heparan
sulfat
present
host
cell
therebi
block
hsv
attach
cell
inhibit
viral
entri
report
partial
neg
charg
zno
micronanostructur
mnss
arrest
vitro
gold
nanoparticl
conjug
tannic
acid
reduc
infect
vitro
vivo
due
high
affin
interact
tannin
hsv
glycoprotein
prevent
attach
entri
hsv
suscept
cell
sinc
hsv
glycoprotein
spike
averag
space
nm
centertocent
tannic
acidmodifi
gold
nanoparticl
diamet
nm
best
antivir
effect
sinc
therapeut
use
treatment
hsv
infectionsacyclovir
peniclovir
oxyresveratrolhav
slow
absorpt
gastrointestin
tract
consecut
low
oral
bioavail
new
approach
consid
usag
polymer
nanoparticl
encapsul
convent
antivir
drug
polycaprolacton
matric
nm
spheric
carboxyl
cyclodextrinbas
nanospong
contain
acyclovir
show
better
effici
clinic
isol
hsv
microemuls
introduc
acyclovir
could
use
effect
topic
prepar
also
microemulsionbas
topic
formul
introduc
penciclovir
show
increas
penetr
penciclovir
mous
skin
idoxuridin
liposom
carrier
also
show
increas
retent
idoxuridin
skin
compar
classic
prepar
mice
shown
intravagin
administr
poli
lacticcoglycol
acid
nanoparticl
encapsul
sirna
knockdown
hostcel
protein
nectin
effect
prevent
genit
infect
expect
usag
innov
nanomedicin
great
posit
effect
treatment
erad
infecti
diseas
nanoparticl
could
improv
efficaci
antivir
drug
reduc
advers
side
effect
drug
characterist
nanoparticl
relev
antivir
therapi
high
dose
drug
need
drug
often
expens
usag
nanoparticul
carrier
reduc
frequenc
drug
intak
time
treatment
enhanc
effect
approv
antivir
therapeut
overcom
limit
low
bioavail
main
object
futur
research
antivir
therapi
find
new
technolog
character
nanomateri
develop
highli
biocompat
biodegrad
nanocarri
system
cytotox
develop
nanocarri
effect
target
specif
site
viral
infect
thu
reduc
drug
toxic
tissu
design
nanomolecul
besid
role
deliveri
possess
intrins
antivir
therapeut
characterist
dendrim
metal
nanoparticl
akhtar
j
shukla
viral
entri
mechan
cellular
viral
mediat
herp
simplex
viru
entri
feb
j
antoin
te
mishra
yk
trigilio
j
tiwari
v
adelung
r
shukla
prophylact
therapeut
neutral
effect
zinc
oxid
tetrapod
structur
herp
simplex
viru
infect
antivir
re
